Circulating biomarkers in osteosarcoma: New translational tools for diagnosis and treatment

Lavinia Raimondi, Angela De Luca, Viviana Costa, Nicola Amodio, Valeria Carina, Daniele Bellavia, Pierfrancesco Tassone, Stefania Pagani, Milena Fini, Riccardo Alessandro, Gianluca Giavaresi

Research output: Contribution to journalReview article

Abstract

Osteosarcoma (OS) is a rare primary malignant bone tumour arising from primitive bone-forming mesenchymal cells, with high incidence in children and young adults, accounting for approximately 60% of all malignant bone tumours. Currently, long-term disease-free survival can be achieved by surgical treatment plus chemotherapy in approximately 60% of patients with localized extremity disease, and in 20-30% of patients with metastatic lung or bone disease. Diagnosis of primary lesions and recurrences is achieved by using radiological investigations and standard tissue biopsy, the latter being costly, painful and hardly repeatable for patients. Therefore, despite some recent advances, novel biomarkers for OS diagnosis, prediction of response to therapy, disease progression and chemoresistance, are urgently needed. Biological fluids such as blood represent a rich source of noninvasive cancer biomarkers, which allow to understand what is really happening inside the tumour, either at diagnosis or during disease progression. In this regard, liquid biopsy potentially represents an alternative and non-invasive method to detect tumour onset, progression and response to therapy. In this review, we will summarize the state of the art in this novel area, illustrating recent studies on OS. Although the data reported in literature seem preliminary, liquid biopsy represents a promising tool with the potential to be rapidly translated in the clinical practice.

Original languageEnglish
Pages (from-to)100831-100851
Number of pages21
JournalOncotarget
Volume8
Issue number59
DOIs
Publication statusPublished - Aug 3 2017

Fingerprint

Osteosarcoma
Biomarkers
Biopsy
Bone and Bones
Disease Progression
Neoplasms
Bone Diseases
Therapeutics
Tumor Biomarkers
Lung Diseases
Disease-Free Survival
Young Adult
Extremities
Recurrence
Drug Therapy
Incidence

Keywords

  • Biomarkers
  • Blood serum
  • Liquid biopsy
  • Osteosarcoma
  • Personalized medicine

ASJC Scopus subject areas

  • Oncology

Cite this

Circulating biomarkers in osteosarcoma : New translational tools for diagnosis and treatment. / Raimondi, Lavinia; De Luca, Angela; Costa, Viviana; Amodio, Nicola; Carina, Valeria; Bellavia, Daniele; Tassone, Pierfrancesco; Pagani, Stefania; Fini, Milena; Alessandro, Riccardo; Giavaresi, Gianluca.

In: Oncotarget, Vol. 8, No. 59, 03.08.2017, p. 100831-100851.

Research output: Contribution to journalReview article

Raimondi, Lavinia ; De Luca, Angela ; Costa, Viviana ; Amodio, Nicola ; Carina, Valeria ; Bellavia, Daniele ; Tassone, Pierfrancesco ; Pagani, Stefania ; Fini, Milena ; Alessandro, Riccardo ; Giavaresi, Gianluca. / Circulating biomarkers in osteosarcoma : New translational tools for diagnosis and treatment. In: Oncotarget. 2017 ; Vol. 8, No. 59. pp. 100831-100851.
@article{1466b777a22d4a288433a4af06b733ab,
title = "Circulating biomarkers in osteosarcoma: New translational tools for diagnosis and treatment",
abstract = "Osteosarcoma (OS) is a rare primary malignant bone tumour arising from primitive bone-forming mesenchymal cells, with high incidence in children and young adults, accounting for approximately 60{\%} of all malignant bone tumours. Currently, long-term disease-free survival can be achieved by surgical treatment plus chemotherapy in approximately 60{\%} of patients with localized extremity disease, and in 20-30{\%} of patients with metastatic lung or bone disease. Diagnosis of primary lesions and recurrences is achieved by using radiological investigations and standard tissue biopsy, the latter being costly, painful and hardly repeatable for patients. Therefore, despite some recent advances, novel biomarkers for OS diagnosis, prediction of response to therapy, disease progression and chemoresistance, are urgently needed. Biological fluids such as blood represent a rich source of noninvasive cancer biomarkers, which allow to understand what is really happening inside the tumour, either at diagnosis or during disease progression. In this regard, liquid biopsy potentially represents an alternative and non-invasive method to detect tumour onset, progression and response to therapy. In this review, we will summarize the state of the art in this novel area, illustrating recent studies on OS. Although the data reported in literature seem preliminary, liquid biopsy represents a promising tool with the potential to be rapidly translated in the clinical practice.",
keywords = "Biomarkers, Blood serum, Liquid biopsy, Osteosarcoma, Personalized medicine",
author = "Lavinia Raimondi and {De Luca}, Angela and Viviana Costa and Nicola Amodio and Valeria Carina and Daniele Bellavia and Pierfrancesco Tassone and Stefania Pagani and Milena Fini and Riccardo Alessandro and Gianluca Giavaresi",
year = "2017",
month = "8",
day = "3",
doi = "10.18632/oncotarget.19852",
language = "English",
volume = "8",
pages = "100831--100851",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals LLC",
number = "59",

}

TY - JOUR

T1 - Circulating biomarkers in osteosarcoma

T2 - New translational tools for diagnosis and treatment

AU - Raimondi, Lavinia

AU - De Luca, Angela

AU - Costa, Viviana

AU - Amodio, Nicola

AU - Carina, Valeria

AU - Bellavia, Daniele

AU - Tassone, Pierfrancesco

AU - Pagani, Stefania

AU - Fini, Milena

AU - Alessandro, Riccardo

AU - Giavaresi, Gianluca

PY - 2017/8/3

Y1 - 2017/8/3

N2 - Osteosarcoma (OS) is a rare primary malignant bone tumour arising from primitive bone-forming mesenchymal cells, with high incidence in children and young adults, accounting for approximately 60% of all malignant bone tumours. Currently, long-term disease-free survival can be achieved by surgical treatment plus chemotherapy in approximately 60% of patients with localized extremity disease, and in 20-30% of patients with metastatic lung or bone disease. Diagnosis of primary lesions and recurrences is achieved by using radiological investigations and standard tissue biopsy, the latter being costly, painful and hardly repeatable for patients. Therefore, despite some recent advances, novel biomarkers for OS diagnosis, prediction of response to therapy, disease progression and chemoresistance, are urgently needed. Biological fluids such as blood represent a rich source of noninvasive cancer biomarkers, which allow to understand what is really happening inside the tumour, either at diagnosis or during disease progression. In this regard, liquid biopsy potentially represents an alternative and non-invasive method to detect tumour onset, progression and response to therapy. In this review, we will summarize the state of the art in this novel area, illustrating recent studies on OS. Although the data reported in literature seem preliminary, liquid biopsy represents a promising tool with the potential to be rapidly translated in the clinical practice.

AB - Osteosarcoma (OS) is a rare primary malignant bone tumour arising from primitive bone-forming mesenchymal cells, with high incidence in children and young adults, accounting for approximately 60% of all malignant bone tumours. Currently, long-term disease-free survival can be achieved by surgical treatment plus chemotherapy in approximately 60% of patients with localized extremity disease, and in 20-30% of patients with metastatic lung or bone disease. Diagnosis of primary lesions and recurrences is achieved by using radiological investigations and standard tissue biopsy, the latter being costly, painful and hardly repeatable for patients. Therefore, despite some recent advances, novel biomarkers for OS diagnosis, prediction of response to therapy, disease progression and chemoresistance, are urgently needed. Biological fluids such as blood represent a rich source of noninvasive cancer biomarkers, which allow to understand what is really happening inside the tumour, either at diagnosis or during disease progression. In this regard, liquid biopsy potentially represents an alternative and non-invasive method to detect tumour onset, progression and response to therapy. In this review, we will summarize the state of the art in this novel area, illustrating recent studies on OS. Although the data reported in literature seem preliminary, liquid biopsy represents a promising tool with the potential to be rapidly translated in the clinical practice.

KW - Biomarkers

KW - Blood serum

KW - Liquid biopsy

KW - Osteosarcoma

KW - Personalized medicine

UR - http://www.scopus.com/inward/record.url?scp=85034651700&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85034651700&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.19852

DO - 10.18632/oncotarget.19852

M3 - Review article

AN - SCOPUS:85034651700

VL - 8

SP - 100831

EP - 100851

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 59

ER -